Table 2.
Patient demographics and cohort characteristics.
| Pts with biopsy at pre-study Screening phase (n= 230) |
PTs with biopsy on treatment (n = 117) |
||
|---|---|---|---|
| Age | median (min - max) |
58 (21 - 86) |
58 (23 - 81) |
| Sex | male female |
118 (52%) 111 (48%) |
59 (46%) 50 (54%) |
| ECOG | 0 | 99 (43.0%) | 46 (42.2%) |
| 1 | 129 (56.1%) | 62 (56.9%) | |
| missing | 2 (0.9%) | 1 (0.9%) | |
| Lines of treatment | 1 | 35 (16%) | 10 (9.2%) |
| 2-3 | 86 (38%) | 39 (35.8%) | |
| 4-5 | 47 (20%) | 27 (24.8%) | |
| 6-9 | 22 (10%) | 11 (10.1%) | |
| > 9 (max 17) | 6 (2%) | 5 (4.6%) | |
| missing | 34 (14%) | 17 (15.6%) | |
| # of metastasis at screening | 0 | 18 (8%) | 10 (9.2%) |
| 1-3 | 129 (56%) | 67 (61.5%) | |
| 5-8 | 59 (26%) | 26 (23.9%) | |
| > 8 | 23 (10%) | 6 (5.5%) | |
| missing | 1 (0%) | 0 (0%) | |
| CPI pre-treatment (all approved anti PD1, PD-L1 or CTLA-4 therapies) | yes | 58 (26%) | 22 (20.2%) |
| no | 164 (72%) | 84 (77.1%) | |
| un- documented | 8 (4%) | 3 (2.8%) | |
| Previous systemic cancer therapy, n (%) | No | 35 (15.2%) | 18 (16.5%) |
| Yes | 195 (84.8%) | 91 (83.5%) | |
| previous Radiotherapy | No | 112 (48%) | 52 (47.7%) |
| Yes | 118 (52%) | 57 (52.3%) | |
This table lists patient demographics and cohort characteristics of the patients giving the metastatic biopsy samples as part of their participation in Phase I clinical trials sponsored by Roche.